Guides
How to choose a safe stem cell clinic
Choose a provider by verifying the exact product, indication, regulatory route, clinical team and follow-up. A polished website, clinic registration or manufacturing claim cannot answer those questions.
Begin with three identities: the legal healthcare provider, the responsible clinician and the exact cell or tissue product. Verify each through the relevant official register. Company registration shows that an entity exists; it does not establish authority to practise medicine or authorisation of a product for your condition.
Ask whether the proposed use is covered by an EMA marketing authorisation, an authorised clinical trial or a specific national hospital exemption. Check the exact indication and site. The EMA/HMA warning on unregulated ATMPs identifies inability to confirm one of these routes as a warning sign.
For a trial, search the official CTIS public portal. Match the sponsor, site, EU trial number, status and intervention. A record may describe research that is completed, not recruiting or unrelated to the commercial offer; read the actual entry.
Request product-specific manufacturing and release information: cell source, donor testing where relevant, processing, identity, viability or other justified specifications, sterility controls, traceability and transport. GMP is a manufacturing requirement in applicable routes, not proof of efficacy, product authorisation or suitability for you. A logo or undated certificate is not enough.
Verify professional qualifications and condition-specific responsibility. Ask who performs assessment, administration, monitoring and emergency escalation. Publication history or years in practice may provide context but cannot replace current licensure, a lawful protocol or product evidence.
Read consent and patient information before payment. They should distinguish known facts from uncertainty, describe alternatives and risks, explain withdrawal and data use, and identify compensation or insurance arrangements where applicable. Sales staff should not answer questions reserved for the investigator or treating physician.
Demand a written follow-up and adverse-event plan that works after you return home. It should name contacts, response times, records supplied to your usual clinician and responsibility for complications. Remote follow-up is useful only when escalation to appropriate local care is defined.
Treat price, testimonials and urgency as commercial signals, not evidence. Red flags include guaranteed outcomes, one product marketed for many unrelated conditions, experimental use outside an authorised trial, refusal to identify the product, pressure to pay immediately and discouraging an independent second opinion.
Use the cost worksheet, then verify the exact product, evidence, legal route and written quotation with an independent qualified clinician.
Sources & further reading
- Stem-cell trials registry (ClinicalTrials.gov) ↗
- Peer-reviewed research (PubMed) ↗
- ISSCR — patient resources ↗
- FDA — consumer guidance ↗
- EMA — ATMP framework ↗
Educational guide; most uses are investigational. Verify the exact product, indication and provider with current regulator records and an independent qualified physician.